Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma
Patients with advanced MCC have a substantial risk of disease progression following treatment discontinuation despite initial favorable ICB response, particularly in those that achieve less than a CR. Most of these patients maintain sensitivity to retreatment with the same drug class. Virus-positive MCC may be a risk factor for post-discontinuation relapse, which should be validated in future studies.
Authors
- Matthew Nichols
- Ahmad A. Tarhini (ORCID: https://orcid.org/0000-0002-3193-9702)
- Zeynep Eroglu (ORCID: https://orcid.org/0000-0002-2307-7030)
- Andrew Scott Brohl (ORCID: https://orcid.org/0000-0002-0071-0534)
- Kenneth Yee Tsai (ORCID: https://orcid.org/0000-0001-5325-212X)
- Evan Wuthrick (ORCID: https://orcid.org/0000-0002-0838-9634)
- Joseph Markowitz (ORCID: https://orcid.org/0000-0003-2490-5464)
- Nikhil I. Khushalani (ORCID: https://orcid.org/0000-0002-3636-4143)
- Vernon K. Sondak (ORCID: https://orcid.org/0000-0003-1090-484X)
- Tanya Ramadoss
- Lilit Karapetyan (ORCID: https://orcid.org/0000-0001-8530-0907)
- Christian Palacios
Institutions
- Nova Southeastern University (US)
- Moffitt Cancer Center (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1136/jitc-2024-009816
- Citations
- 10
- Primary Topic
- Polyomavirus and related diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.83